

Reference:	FOI.16185.24
Subject:	Asthma treatments
Date of Request:	12 December 2024

Requested:

1. How many patients have been treated (for any condition) in the last 4 months with:
 - Benralizumab
 - Dupilumab
 - Omalizumab
 - Reslizumab
 - Mepolizumab
 - Tezepelumab

2. Of the patients treated in the last 4 months with any of the above products, please provide the number of patients by the following age-groups:
 - Age 6-11
 - Age 12-17
 - Age 18 and above

3. How many patients have been treated in the last 4 months by the Respiratory Medicine department ONLY with:
 - Dupilumab
 - Omalizumab

4. How many patients have been diagnosed with BOTH chronic sinusitis (ICD-10 code J32) AND nasal polyps (ICD-10 code J33) in the past year?
 - a. Of these patients, how many have been treated in the last 4 months with:
 - Benralizumab
 - Dupilumab
 - Omalizumab
 - Reslizumab
 - Mepolizumab
 - Tezepelumab

Response:

1. Hywel Dda University Health Board (UHB) provides, within the table below, the number of patients that have been treated for any condition, with the listed medications within Secondary Care, during the period 1 August to 30 November 2024.

Medication	Number
Benralizumab	86
Dupilumab	109

Omalizumab	21
Reslizumab	0
Mepolizumab	28
Tezepelumab	68

2. The UHB provides, within the table below, the number of patients that received the medications in question 1 within Secondary Care, by the age ranges 6 to 17 and 18 and over, during the period 1 August to 30 November 2024.

Age range	Number
6 to 17	14
18 and over	298

The UHB has provided data for the grouped age range of 6 to 17 years, as opposed to the requested age groups of 6 to 11 and 12 to 17, due to the low numbers of cases (5 or less), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000 (FoIA). This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

3. The UHB provides, within the table below, the number of respiratory patients that have been treated with the medications listed within Secondary Care, during the period 1 August to 30 November 2024.

Medication	Number
Dupilumab	12
Omalizumab	0

4. The UHB confirms that seven (7) patients have been diagnosed with both chronic sinusitis and nasal polyps, as recorded on the UHB's Welsh Patient Administration System (WPAS) within Secondary Care, during the period 1 November 2023 to 31 October 2024. (The date range provided is the most up to date period available; this is due to a standard clinical coding backlog of up to three (3) months.)

The UHB confirms that none of the patients identified in question 4 received the medications listed, during the period 1 August to 30 November 2024.